Last reviewed · How we verify
Paclitaxel Nanoparticle Albumin Bound — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Paclitaxel Nanoparticle Albumin Bound (Paclitaxel Nanoparticle Albumin Bound) — Celgene.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Paclitaxel Nanoparticle Albumin Bound TARGET | Paclitaxel Nanoparticle Albumin Bound | Celgene | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Paclitaxel Nanoparticle Albumin Bound CI watch — RSS
- Paclitaxel Nanoparticle Albumin Bound CI watch — Atom
- Paclitaxel Nanoparticle Albumin Bound CI watch — JSON
- Paclitaxel Nanoparticle Albumin Bound alone — RSS
Cite this brief
Drug Landscape (2026). Paclitaxel Nanoparticle Albumin Bound — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-nanoparticle-albumin-bound. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab